Publications by authors named "R Paul Wadwa"
Article Synopsis
- A modified Control-IQ system for managing type 1 diabetes was tested in adults, adolescents, children, and preschoolers across a multicenter trial to evaluate the effects of a lower treatment range and a new late bolus feature.
- The study involved 72 participants who used two different treatment ranges (standard and lower) for two weeks each, with meal challenges performed to assess the new bolus feature.
- Results showed that using the lower treatment range significantly improved time in range (TIR) and time in tight range (TITR) for managing glucose levels, with no severe complications reported.
Article Synopsis
- Youth with type 1 diabetes often struggle to meet glycemic targets, even with advanced technologies like continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) insulin systems, primarily due to issues like nocturnal alarm fatigue that disrupt sleep.
- A study involving 76 pediatric patients revealed that the frequency of nighttime alarms increased significantly after starting the HCL system, with an average of 5.4 alarms per night in automated mode, leading to decreased overall device use.
- Findings suggest that these frequent alarms negatively impact sleep quality and device adherence, indicating a need for further research to explore how diabetes technology affects sleep and ways to enhance sleep quality while using such technologies.
Objective: To examine the cross-sectional associations between diabetes distress, BMI (zBMI; BMI z-score), objectively measured mean daily blood glucose readings and insulin boluses administered, and A1C in adolescents with type 1 diabetes (T1D) using insulin pumps.
Methods: T1D self-management behaviour data were downloaded from adolescents' (N = 79) devices and mean daily frequency of blood glucose readings and insulin boluses were calculated. Diabetes distress was measured (Problem Areas in Diabetes-Teen questionnaire [PAID-T]), A1C collected, and zBMI calculated from height and weight.
Background/objective: The main objective of this study is to evaluate the incremental cost-effectiveness (ICER) of the Cambridge hybrid closed-loop automated insulin delivery (AID) algorithm versus usual care for children and adolescents with type 1 diabetes (T1D).
Methods: This multicenter, binational, parallel-controlled trial randomized 133 insulin pump using participants aged 6 to 18 years to either AID (n = 65) or usual care (n = 68) for 6 months. Both within-trial and lifetime cost-effectiveness were analyzed.
Background: Rebound hyperglycemia may occur following glucagon treatment for severe hypoglycemia. We assessed rebound hyperglycemia occurrence after nasal glucagon (NG) or injectable glucagon (IG) administration in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: This was a pooled analysis of 3 multicenter, randomized, open-label studies (NCT03339453, NCT03421379, NCT01994746) in patients ≥18 years with T1D or T2D with induced hypoglycemia.